Risk factor
Low price volatility
Profitability factor
Solid dividends
About
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral o
Target Price
The average target price of 4569.T is 1300 and suggests 13% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio